Aclarion Reports Strong Q3 Growth and Expands CLARITY Trial

A healthcare technology company, Aclarion, Inc., announced a strong third quarter performance, with significant growth in its scan volume and a robust balance sheet. The company reported an 85% year-over-year increase in scan volume for the third quarter of 2026, which contributed to a 117% growth for the nine months ended September 30, 2026. This growth underscores the growing interest among physicians in Aclarion’s Nociscan platform, which uses Magnetic Resonance Spectroscopy (MRS) to help identify the location of chronic low back pain.

In a Shareholder Letter, Chief Executive Officer Brent Ness highlighted these achievements, emphasizing the importance of Aclarion’s clinical program and its expanding evidence base. The European Spine Journal recently published peer-reviewed data supporting MRS as a viable alternative to provocative discography, adding to Aclarion’s growing body of evidence. This publication further validates Nociscan’s potential to improve patient care and clinical outcomes.

The CLARITY trial, which aims to enroll 300 patients, has expanded to eleven clinical sites, with updated enrollment criteria designed to accelerate recruitment and enhance the study’s real-world applicability. Aclarion’s commitment to the CLARITY trial is reflected in its ongoing efforts to refine the inclusion and exclusion criteria, with the aim of achieving meaningful improvements in recruitment. The company’s financial health is also evident, with $14.2 million in cash reserves providing a strong runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial.

Aclarion’s continued commercial traction and expanding clinical evidence base are crucial in supporting reimbursement initiatives in both the United Kingdom and the United States. The company’s balanced approach to capital allocation and investment in sustainable shareholder value is a testament to its forward-thinking strategy. Aclarion’s strong balance sheet and disciplined financial management position it to continue its momentum in the years ahead.

Aclarion, a healthcare technology company leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, has reported impressive growth in its scan volume and a robust financial position. The company’s CLARITY trial has expanded to eleven clinical sites, with updated enrollment criteria designed to accelerate recruitment and enhance the study’s real-world applicability. Aclarion’s financial health is bolstered by $14.2 million in cash reserves, providing a strong runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial. The company’s continued commercial success and expanding clinical evidence base are instrumental in supporting reimbursement initiatives in both the United Kingdom and the United States. Aclarion’s balanced approach to capital allocation and investment in sustainable shareholder value positions it well for continued growth.